Pancreatic Cancer

The tolerability of nab-paclitaxel and gemcitabine has opened the door to a host of novel combination strategies that use the two agents as a backbone.

With the wealth of data demonstrating efficacy in the metastatic setting, researchers are now assessing nab-paclitaxel/gemcitabine as both an adjuvant and neoadjuvant treatment for patients with pancreatic cancer.

First-line therapies with improved efficacy might encourage use of second-line treatment in a larger proportion of patients with advanced pancreatic cancer.

A multitude of factors contribute to the selection of frontline treatment for patients with advanced pancreatic cancer, specifically in regard to selecting first- and second-line therapies.

Given the benefits of nab-paclitaxel plus gemcitabine and FOLFIRINOX, efforts have been made to improve the toxicity profiles through dose modifications.

Frontline therapies for patients with metastatic pancreatic cancer have advanced in the past 5 years, with the FDA approval of nab-paclitaxel plus gemcitabine.

Evolving Paradigms in Pancreatic Cancer: References